Enhanced antitumor effect of dendritic cell based immunotherapy after intratumoral injection of radionuclide Ho-166 against B16 melanoma

Tae Hyung Lee, Young Hun Cho, Jong Doo Lee, Woo Ick Yang, Jong Lan Shin, Mingeol Lee

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

Internal radiotherapy with the intratumoral injection of the beta-emitting radionuclide, Holmium (Ho)-166, into B16 melanoma resulted in a reduction in size and growth rate; however, complete remission was not always achieved. Therefore, additional dendritic cell (DC) therapy was investigated to determine whether it could improve therapeutic results. Malignant melanoma was induced in mice by inoculating B16F10 cell line subcutaneously. Fifty-four mice were divided into four groups: (1) non-treated (group I, n = 11), (2) treated with Ho-166 (group II, n = 16), (3) treated with immature DCs (group III, n = 8), and (4) treated with immature DCs after Ho-166 injection (group IV, n = 19). Changes in tumor size, survival rates, and immunologic profiles were observed. Nineteen days after Ho-166 or PBS injection, mean tumor sizes in the four groups were 6044 ± 1046, 1658 ± 523, 3871 ± 921, and 444 ± 167 mm3, respectively. We observed a significant decrease in tumor size (P < 0.05) and an increase in survival in group IV. When the B16F10 cell line was reinjected into the contralateral backs of survivors, much slower growth was observed in group IV (P < 0.05). Both tumor-specific CTL and natural killer cell activities and the infiltration of inflammatory cells into tumor tissues were found to be elevated in group IV. In addition, strong immune responses as determined by in vitro T cell proliferation, ELISA and ELISPOT assay were induced in group IV. Our results suggest that a combination of internal radiotherapy using Ho-166 and immature DCs could be used either to treat unresectable melanoma or as an adjuvant therapy after surgery.

Original languageEnglish
Pages (from-to)19-26
Number of pages8
JournalImmunology Letters
Volume106
Issue number1
DOIs
Publication statusPublished - 2006 Jul 15

Fingerprint

Holmium
Experimental Melanomas
Radioisotopes
Immunotherapy
Dendritic Cells
Injections
Neoplasms
Melanoma
Radiotherapy
Enzyme-Linked Immunospot Assay
Cell Line
Growth
Cell- and Tissue-Based Therapy
Natural Killer Cells
Enzyme-Linked Immunosorbent Assay
Cell Proliferation
T-Lymphocytes
Therapeutics

All Science Journal Classification (ASJC) codes

  • Immunology and Allergy
  • Immunology

Cite this

Lee, Tae Hyung ; Cho, Young Hun ; Lee, Jong Doo ; Yang, Woo Ick ; Shin, Jong Lan ; Lee, Mingeol. / Enhanced antitumor effect of dendritic cell based immunotherapy after intratumoral injection of radionuclide Ho-166 against B16 melanoma. In: Immunology Letters. 2006 ; Vol. 106, No. 1. pp. 19-26.
@article{ff7394f17766443e94c62df125231d49,
title = "Enhanced antitumor effect of dendritic cell based immunotherapy after intratumoral injection of radionuclide Ho-166 against B16 melanoma",
abstract = "Internal radiotherapy with the intratumoral injection of the beta-emitting radionuclide, Holmium (Ho)-166, into B16 melanoma resulted in a reduction in size and growth rate; however, complete remission was not always achieved. Therefore, additional dendritic cell (DC) therapy was investigated to determine whether it could improve therapeutic results. Malignant melanoma was induced in mice by inoculating B16F10 cell line subcutaneously. Fifty-four mice were divided into four groups: (1) non-treated (group I, n = 11), (2) treated with Ho-166 (group II, n = 16), (3) treated with immature DCs (group III, n = 8), and (4) treated with immature DCs after Ho-166 injection (group IV, n = 19). Changes in tumor size, survival rates, and immunologic profiles were observed. Nineteen days after Ho-166 or PBS injection, mean tumor sizes in the four groups were 6044 ± 1046, 1658 ± 523, 3871 ± 921, and 444 ± 167 mm3, respectively. We observed a significant decrease in tumor size (P < 0.05) and an increase in survival in group IV. When the B16F10 cell line was reinjected into the contralateral backs of survivors, much slower growth was observed in group IV (P < 0.05). Both tumor-specific CTL and natural killer cell activities and the infiltration of inflammatory cells into tumor tissues were found to be elevated in group IV. In addition, strong immune responses as determined by in vitro T cell proliferation, ELISA and ELISPOT assay were induced in group IV. Our results suggest that a combination of internal radiotherapy using Ho-166 and immature DCs could be used either to treat unresectable melanoma or as an adjuvant therapy after surgery.",
author = "Lee, {Tae Hyung} and Cho, {Young Hun} and Lee, {Jong Doo} and Yang, {Woo Ick} and Shin, {Jong Lan} and Mingeol Lee",
year = "2006",
month = "7",
day = "15",
doi = "10.1016/j.imlet.2006.03.007",
language = "English",
volume = "106",
pages = "19--26",
journal = "Immunology Letters",
issn = "0165-2478",
publisher = "Elsevier",
number = "1",

}

Enhanced antitumor effect of dendritic cell based immunotherapy after intratumoral injection of radionuclide Ho-166 against B16 melanoma. / Lee, Tae Hyung; Cho, Young Hun; Lee, Jong Doo; Yang, Woo Ick; Shin, Jong Lan; Lee, Mingeol.

In: Immunology Letters, Vol. 106, No. 1, 15.07.2006, p. 19-26.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Enhanced antitumor effect of dendritic cell based immunotherapy after intratumoral injection of radionuclide Ho-166 against B16 melanoma

AU - Lee, Tae Hyung

AU - Cho, Young Hun

AU - Lee, Jong Doo

AU - Yang, Woo Ick

AU - Shin, Jong Lan

AU - Lee, Mingeol

PY - 2006/7/15

Y1 - 2006/7/15

N2 - Internal radiotherapy with the intratumoral injection of the beta-emitting radionuclide, Holmium (Ho)-166, into B16 melanoma resulted in a reduction in size and growth rate; however, complete remission was not always achieved. Therefore, additional dendritic cell (DC) therapy was investigated to determine whether it could improve therapeutic results. Malignant melanoma was induced in mice by inoculating B16F10 cell line subcutaneously. Fifty-four mice were divided into four groups: (1) non-treated (group I, n = 11), (2) treated with Ho-166 (group II, n = 16), (3) treated with immature DCs (group III, n = 8), and (4) treated with immature DCs after Ho-166 injection (group IV, n = 19). Changes in tumor size, survival rates, and immunologic profiles were observed. Nineteen days after Ho-166 or PBS injection, mean tumor sizes in the four groups were 6044 ± 1046, 1658 ± 523, 3871 ± 921, and 444 ± 167 mm3, respectively. We observed a significant decrease in tumor size (P < 0.05) and an increase in survival in group IV. When the B16F10 cell line was reinjected into the contralateral backs of survivors, much slower growth was observed in group IV (P < 0.05). Both tumor-specific CTL and natural killer cell activities and the infiltration of inflammatory cells into tumor tissues were found to be elevated in group IV. In addition, strong immune responses as determined by in vitro T cell proliferation, ELISA and ELISPOT assay were induced in group IV. Our results suggest that a combination of internal radiotherapy using Ho-166 and immature DCs could be used either to treat unresectable melanoma or as an adjuvant therapy after surgery.

AB - Internal radiotherapy with the intratumoral injection of the beta-emitting radionuclide, Holmium (Ho)-166, into B16 melanoma resulted in a reduction in size and growth rate; however, complete remission was not always achieved. Therefore, additional dendritic cell (DC) therapy was investigated to determine whether it could improve therapeutic results. Malignant melanoma was induced in mice by inoculating B16F10 cell line subcutaneously. Fifty-four mice were divided into four groups: (1) non-treated (group I, n = 11), (2) treated with Ho-166 (group II, n = 16), (3) treated with immature DCs (group III, n = 8), and (4) treated with immature DCs after Ho-166 injection (group IV, n = 19). Changes in tumor size, survival rates, and immunologic profiles were observed. Nineteen days after Ho-166 or PBS injection, mean tumor sizes in the four groups were 6044 ± 1046, 1658 ± 523, 3871 ± 921, and 444 ± 167 mm3, respectively. We observed a significant decrease in tumor size (P < 0.05) and an increase in survival in group IV. When the B16F10 cell line was reinjected into the contralateral backs of survivors, much slower growth was observed in group IV (P < 0.05). Both tumor-specific CTL and natural killer cell activities and the infiltration of inflammatory cells into tumor tissues were found to be elevated in group IV. In addition, strong immune responses as determined by in vitro T cell proliferation, ELISA and ELISPOT assay were induced in group IV. Our results suggest that a combination of internal radiotherapy using Ho-166 and immature DCs could be used either to treat unresectable melanoma or as an adjuvant therapy after surgery.

UR - http://www.scopus.com/inward/record.url?scp=33746227735&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33746227735&partnerID=8YFLogxK

U2 - 10.1016/j.imlet.2006.03.007

DO - 10.1016/j.imlet.2006.03.007

M3 - Article

C2 - 16647143

AN - SCOPUS:33746227735

VL - 106

SP - 19

EP - 26

JO - Immunology Letters

JF - Immunology Letters

SN - 0165-2478

IS - 1

ER -